Indian Stock NSE ,MCX,Ncdex,Forex,Comex Mareket Updates

A Comprehensive Technical Analysis Programmes aimed to make you a Profitable Trader and achieve 100% return per annum on your Investment IN MCX & STOCK MARKET SPECIALLY IN GOLD MARKET

TRAINING IS GOING ON TAMILNADU, KERALA,KARNATAKA MORE DETAILS@09952833280/09042689098

In1978 sensex @100 after 10years in 1988 100*6 sensex @600 in 1998 600*6 sensex@3600 in 2008 3600*6 sensex@21600 then in 2018 sensex 129600......
A Comprehensive Technical Analysis Programmes aimed to make you a Profitable Trader and achieve 100% return per annum on your Investment IN MCX & STOCK MARKET SPECIALLY IN GOLD MARKET


No one beat our accuracy, Still why u r waiting? join us. Grow with Us with profit.Our clients made massive profit with our calls

If U Want Nifty & Stock Option calls &MCX & NCDEX COMMODITY daily ADD me On JANURAM@GMAIL.COM & JMSQUARENIFTY@yahoo.com & JMSQUARENIFTYGOLD@yahoo.com Contact Me@9952833280&9042689098


Disclaimer

Ours is an advisory role. The final decision and consequences based on our Information is solely yours. Moreover, in keeping with regulatory guidelines, we do not guarantee any returns on investments. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.


2008-06-16

Goodbye to high BP and obesity

Can a single pill treat problems of high blood pressure, reduce cholesterol level and act as a blood thinner? Seems like this may be possible soon. In one of the largest clinical trials being conducted for the first time, the impact of the ’wonder drug’ is being assessed across 20 cities in India.


The trials of the drug ’polypack’ manufactured by Cadila Pharmaceuticals are being conducted on 2,000 subjects, between the age of 45 and 80 years, who have any one of the risk factors - age, obesity, high blood pressure, high cholesterol or high blood sugar.


The ’polypack’ contains a combination of five drugs in eight different formulations (three blood pressure lowering agents, an antiplatelet drug, a beta blocker, an ACE inhibitor, a diuretic and a statin) for treating cardio-vascular conditions such as reducing blood pressure and lowering cholesterol levels.


Simply put, the polypack includes blood pressure lowering combinations, aspirin (blood thinner) and a statin, which is a cholesterol lowering agent.


The trials are being conducted by St John Research Institute, Bangalore and Canada-based Population Health Research Institute.


"We need to assess the impact (efficacy) of the different combinations on an individual who has cardio-vascular risk factors, and also the safety of these drugs taken together. The side-effects of the five medicines will also be studied," says Dr Rajeev Gupta of Fortis Hospital, Jaipur who is involved in the study.


The subjects will be given the combination drug for three months and a follow up will be done in the fourth month. The trials will be completed by July and findings put together by end of the year.


The second phase of trials will assess whether heart attacks and strokes can be prevented with the combination drug, Gupta added.


Cardiovascular diseases are major causes of mortality in the Indian subcontinent, causing over 30% of deaths. It has been predicted that these diseases will increase rapidly and India will contribute to over half the cases of heart diseases in the world within the next 15 years.


Coronary heart disease and stroke have increased in both urban and rural areas. The sharp rise in cardiovascular problems including heart disease and stokes is attributed to increasing number of smokers, obesity with high waist to hip ratio, high blood pressure, high cholesterol, stress and sedentary lifestyle.

No comments:

Disclaimer

Ours is an advisory role. The final decision and consequences based on our Information is solely yours. Moreover, in keeping with regulatory guidelines, we do not guarantee any returns on investments. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.